BOTHELL, Wash.--(BUSINESS WIRE)--BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of the two-year results for the SENTRY trial, at the Vascular Interventional Advances ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. LAS VEGAS — Use of a bioconvertible inferior vena cava ...
BOTHELL, Wash.--(BUSINESS WIRE)--BTG plc (LSE: BTG), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry ...
LAS VEGAS — Use of a bioconvertible inferior vena cava filter successfully prevented new-onset pulmonary embolism in high-risk patients and was bioresorbed within 1 year in most cases, according to ...
LAS VEGAS, NV—Several novel bioresorbable devices were presented here this week at VIVA 2018 in late-breaking trial sessions. One offered a unique way to close large femoral artery access sites ...
in reducing potential complications seen with conventional filters.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results